Appendix SRisks and benefits of treatments for psoriasis

Publication Details

Data are provided for the proportions of people achieving remission, withdrawing due to adverse events and experiencing specific adverse events (as rioritised by the GDG) for interventions that have been recommended in this guideline. Data are based on pooled estimates where possible and from trials with populations and dosing appropriate to the intervention. For full details of the duration of treatment and dosing schedules please refer to the main text of the guideline.

Text is in grey when the GDG had very low confidence in the absolute estimates, for example due to confounding and inadequate sample size.

S.1. Topical therapies (short term) (PDF, 101K)

S.2. Phototherapy (short-term) (PDF, 94K)

S.3. Systemic, non-biologic therapies (short term) (PDF, 98K)

S.4. Systemic, biologic therapies (short term) (PDF, 97K)

S.5. Long-term risks (PDF, 85K)